Forbes magazine has an article on ibrutinib, one of the new drugs for CLL.
Being Forbes magazine there is much detail about how the drug research and development was funded, but it’s still an interesting read.
forbes.com/sites/davidshayw...
Dick
Forbes magazine has an article on ibrutinib, one of the new drugs for CLL.
Being Forbes magazine there is much detail about how the drug research and development was funded, but it’s still an interesting read.
forbes.com/sites/davidshayw...
Dick
Thanks for this Dick.
A fascinating story which is well worth finding the time to read. Rather sobering to learn that the research knowledge that lead to ibrutinib was picked up by Pharmacyclics at zero value and further that animal based research only lead to shaky preclinical results.
Interesting Lessons Learned? section too.
Neil